Oneel Patel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/300714/publications.pdf

Version: 2024-02-01

46 papers	962 citations	361045 20 h-index	454577 30 g-index
47 all docs	47 docs citations	47 times ranked	1422 citing authors

#	Article	IF	Citations
1	Gastrin-releasing peptide and cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 23-41.	3.3	113
2	The Role of Hypoxia-Inducible Factor 1Î± in Determining the Properties of Castrate-Resistant Prostate Cancers. PLoS ONE, 2013, 8, e54251.	1.1	70
3	FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. BMC Cancer, 2016, 16, 24.	1.1	44
4	A pilot doubleâ€blind safety and feasibility randomized controlled trial of highâ€dose intravenous zinc in hospitalized COVIDâ€19 patients. Journal of Medical Virology, 2021, 93, 3261-3267.	2.5	43
5	Gastrinâ€releasing peptide: Different forms, different functions. BioFactors, 2009, 35, 69-75.	2.6	42
6	HIF1Î± Expression under Normoxia in Prostate Cancerâ€" Which Pathways to Target?. Journal of Urology, 2015, 193, 763-770.	0.2	40
7	Protective effect of zinc preconditioning against renal ischemia reperfusion injury is dose dependent. PLoS ONE, 2017, 12, e0180028.	1.1	38
8	Zinc supplementation as an adjunct therapy for COVIDâ€19: Challenges and opportunities. British Journal of Clinical Pharmacology, 2021, 87, 3737-3746.	1.1	37
9	The effects of nonspecific <scp>HIF</scp>1Î± inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Medicine, 2014, 3, 245-251.	1.3	36
10	Expression and function of gastrinâ€releasing peptide (<scp>GRP</scp>) in normal and cancerous urological tissues. BJU International, 2014, 113, 40-47.	1.3	32
11	Synthesis, Expression and Biological Activity of the Prohormone for Gastrin Releasing Peptide (ProGRP). Endocrinology, 2006, 147, 502-509.	1.4	31
12	Stimulation of proliferation and migration of a colorectal cancer cell line by amidated and glycine-extended gastrin-releasing peptide via the same receptor. Biochemical Pharmacology, 2004, 68, 2129-2142.	2.0	30
13	Evolution of gastrointestinal hormones: the cholecystokinin/gastrin family. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 77-88.	1.2	27
14	P21-activated kinase 1 promotes colorectal cancer survival by up-regulation of hypoxia-inducible factor-1Î±. Cancer Letters, 2013, 340, 22-29.	3.2	27
15	C-Terminal Fragments of the Gastrin-Releasing Peptide Precursor Stimulate Cell Proliferation via a Novel Receptor. Endocrinology, 2007, 148, 1330-1339.	1.4	26
16	Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol. BMJ Open, 2020, 10, e040580.	0.8	26
17	Targeting HIF-1Î± to Prevent Renal Ischemia-Reperfusion Injury: Does It Work?. International Journal of Cell Biology, 2018, 2018, 1-7.	1.0	25
18	Gastrin increases its own synthesis in gastrointestinal cancer cells via the CCK2 receptor. FEBS Letters, 2010, 584, 4413-4418.	1.3	23

#	Article	IF	Citations
19	Phylogenetic analysis of the sequences of gastrin-releasing peptide and its receptors: Biological implications. Regulatory Peptides, 2007, 143, 1-14.	1.9	22
20	Normoxic regulation of HIF-1Î± in prostate cancer. Nature Reviews Urology, 2014, 11, 419-419.	1.9	22
21	Production, Secretion, and Biological Activity of the C-Terminal Flanking Peptide of Human Progastrin. Gastroenterology, 2006, 131, 1463-1474.	0.6	20
22	Zinc ions upregulate the hormone gastrin via an E-box motif in the proximal gastrin promoter. Journal of Molecular Endocrinology, 2014, 52, 29-42.	1.1	20
23	Zinc preconditioning protects against renal ischaemia reperfusion injury in a preclinical sheep large animal model. BioMetals, 2018, 31, 821-834.	1.8	16
24	Why is it worth testing the ability of zinc to protect against ischaemia reperfusion injury for human application. Metallomics, 2019, 11, 1330-1343.	1.0	16
25	Induction of Gastrin Expression in Gastrointestinal Cells by Hypoxia or Cobalt Is Independent of Hypoxia-Inducible Factor (HIF). Endocrinology, 2012, 153, 3006-3016.	1.4	15
26	Activation by zinc of the human gastrin gene promoter in colon cancer cells in vitro and in vivo. Metallomics, 2015, 7, 1390-1398.	1.0	15
27	Recombinant C-terminal fragments of the gastrin-releasing peptide precursor are bioactive. Cancer Letters, 2007, 254, 87-93.	3.2	12
28	Zinc ion dyshomeostasis increases resistance of prostate cancer cells to oxidative stress via upregulation of HIF1Î±. Oncotarget, 2018, 9, 8463-8477.	0.8	12
29	Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. BJU International, 2019, 123, 36-42.	1.3	12
30	Preconditioning against renal ischaemia reperfusion injury: the failure to translate to the clinic. Journal of Nephrology, 2019, 32, 539-547.	0.9	12
31	Pro-GRP-Derived Peptides Are Expressed in Colorectal Cancer Cells and Tumors and Are Biologically Active in Vivo. Endocrinology, 2012, 153, 1082-1092.	1.4	10
32	Zinc Ions Mediate Gastrin Expression, Proliferation, and Migration Downstream of the Cholecystokinin-2 Receptor. Endocrinology, 2016, 157, 4706-4719.	1.4	10
33	Gastrin mediates resistance to hypoxia-induced cell death in xenografts of the human colorectal cancer cell line LoVo. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2471-2480.	1.9	9
34	The C-terminal flanking peptide (CTFP) of progastrin inhibits apoptosis via a PI3-kinase-dependent pathway. Regulatory Peptides, 2010, 165, 224-231.	1.9	6
35	The C-terminal flanking peptide of progastrin induces gastric cell apoptosis and stimulates colonic cell division in vivo. Peptides, 2013, 46, 83-93.	1.2	5
36	The Protective Effect of Zinc Against Liver Ischaemia Reperfusion Injury in a Rat Model of Global Ischaemia. Journal of Clinical and Experimental Hepatology, 2020, 10, 228-235.	0.4	5

#	Article	IF	Citations
37	Ferric ions inhibit proteolytic processing of progastrin. Biochemical and Biophysical Research Communications, 2011, 404, 1083-1087.	1.0	4
38	Identification of binding sites for <scp>C</scp>â€terminal proâ€gastrinâ€releasing peptide (<scp>GRP</scp>)â€derived peptides in renal cell carcinoma: a potential target for future therapy. BJU International, 2015, 115, 829-838.	1.3	4
39	Progastrin: a potential predictive marker of liver metastasis in colorectal cancer. International Journal of Colorectal Disease, 2017, 32, 1061-1064.	1.0	4
40	Zinc Preconditioning Provides Cytoprotection following Iodinated Contrast Media Exposure in In Vitro Models. Contrast Media and Molecular Imaging, 2021, 2021, 1-6.	0.4	1
41	Gastrin-Releasing Peptide. , 2011, , 1508-1511.		0
42	Hypoxia-inducible factor 1Î±: A screening tool for predicting development of castrate resistant prostate cancer.. Journal of Clinical Oncology, 2012, 30, e15117-e15117.	0.8	0
43	Effects of angiotensin-converting enzyme (ACE) inhibitors on the outcomes of patients receiving primary radiotherapy for prostate cancer (PC).. Journal of Clinical Oncology, 2013, 31, e16016-e16016.	0.8	0
44	Gastrin-Releasing Peptide. , 2014, , 1-5.		0
45	Gastrin-Releasing Peptide. , 2016, , 1858-1862.		0
46	Experimental rat models for contrast-induced nephropathy; a comprehensive review. Journal of Nephropathology, 2020, 9, e12-e12.	0.1	0